Top Markets
#1 Nesa Nesa +805.14%
#2 Cortex Cortex +68.71%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.68%
#4 QuantixAI QuantixAI +23.71%
#5 Pons Pons +23.63%
#6 EXOD EXOD +22.78%
#7 Instadapp Instadapp +18.46%
#8 Movement Movement +12.30%
#9 The Black Bull The Black Bull +11.32%
#10 PondCoin PondCoin +11.10%
Coin of the day
Nesa Nesa
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Surrozen, Inc. Surrozen, Inc.

Surrozen, Inc.

SRZN
Classement en actions #19464
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Prix de l'action
$21.57
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$161.29M
Changement (1 jour)
3.55%
Changement (1 an)
94.32%
Pays
US
Échange Surrozen, Inc. (SRZN)

Catégorie

Healthcare
Historique du rendement du dividende pour Surrozen, Inc. (SRZN)
Le rendement du dividende (TTM) de Surrozen, Inc. (symbole boursier : SRZN) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Surrozen, Inc. (SRZN) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH